Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.90
-4.0%		$1.98
$1.60
▼
$4.94
$113.76M3.31562,138 shs613,500 shs
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.73
-1.9%		$0.85
$0.57
▼
$2.44
$30.44M0.0694,744 shs13,388 shs
Cibus, Inc. stock logo
CBUS
Cibus
$1.54
-3.1%		$1.72
$1.09
▼
$4.19
$121.52M1.59101,544 shs46,369 shs
Genelux Corporation stock logo
GNLX
Genelux
$2.52
-3.4%		$2.69
$2.29
▼
$8.53
$118.09M0.57298,304 shs115,792 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-4.04%-2.06%-11.63%+11.76%-40.06%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-1.85%+2.51%+2.45%-54.59%-56.23%
Cibus, Inc. stock logo
CBUS
Cibus
-3.14%+1.99%-10.98%+14.93%+14.93%
Genelux Corporation stock logo
GNLX
Genelux
-3.45%+7.69%-7.35%-13.10%-41.94%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$1.90
-4.0%		$1.98
$1.60
▼
$4.94
$113.76M3.31562,138 shs613,500 shs
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
$0.73
-1.9%		$0.85
$0.57
▼
$2.44
$30.44M0.0694,744 shs13,388 shs
Cibus, Inc. stock logo
CBUS
Cibus
$1.54
-3.1%		$1.72
$1.09
▼
$4.19
$121.52M1.59101,544 shs46,369 shs
Genelux Corporation stock logo
GNLX
Genelux
$2.52
-3.4%		$2.69
$2.29
▼
$8.53
$118.09M0.57298,304 shs115,792 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-4.04%-2.06%-11.63%+11.76%-40.06%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-1.85%+2.51%+2.45%-54.59%-56.23%
Cibus, Inc. stock logo
CBUS
Cibus
-3.14%+1.99%-10.98%+14.93%+14.93%
Genelux Corporation stock logo
GNLX
Genelux
-3.45%+7.69%-7.35%-13.10%-41.94%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2.64
Moderate Buy$10.25439.47% Upside
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
1.00
SellN/AN/A
Cibus, Inc. stock logo
CBUS
Cibus
2.00
Hold$9.00484.42% Upside
Genelux Corporation stock logo
GNLX
Genelux
2.80
Moderate Buy$18.00614.29% Upside

Current Analyst Ratings Breakdown

Latest BYSI, CBUS, GNLX, and BDTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/16/2026
Genelux Corporation stock logo
GNLX
Genelux
Lucid Cap Mkts logo
Lucid Cap Mkts
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/3/2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/18/2026
Genelux Corporation stock logo
GNLX
Genelux
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSpeculative Buy
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/6/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/17/2026
Genelux Corporation stock logo
GNLX
Genelux
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/13/2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D) ➝ Sell (D-)
7/8/2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/29/2026
Cibus, Inc. stock logo
CBUS
Cibus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/A$0.51 per share3.76$1.97 per shareN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/A$0.11 per share6.51($0.59) per shareN/A
Cibus, Inc. stock logo
CBUS
Cibus
$3.64M32.34N/AN/A$0.40 per share3.85
Genelux Corporation stock logo
GNLX
Genelux
$10K11,400.48N/AN/A$0.30 per share8.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
$22.37M-$0.75N/AN/AN/AN/A-32.10%-25.21%11/5/2026 (Estimated)
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$1.01M-$0.12N/AN/AN/AN/AN/A-28.88%11/12/2026 (Estimated)
Cibus, Inc. stock logo
CBUS
Cibus
-$127.08M-$1.65N/AN/AN/A-2,258.89%-287.03%-27.99%11/12/2026 (Estimated)
Genelux Corporation stock logo
GNLX
Genelux
-$32.15M-$0.86N/AN/AN/AN/A-205.85%-138.79%11/4/2026 (Estimated)

Latest BYSI, CBUS, GNLX, and BDTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
-$0.54-$0.02+$0.52-$0.02$8.77 millionN/A
8/13/2026Q2 2026
Cibus, Inc. stock logo
CBUS
Cibus
-$0.19-$0.29-$0.10-$0.29$1.70 million$0.99 million
8/13/2026Q2 2026
Genelux Corporation stock logo
GNLX
Genelux
-$0.1967-$0.21-$0.0133-$0.21N/AN/A
8/5/2026Q2 2026
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
-$0.1954-$0.17+$0.0254-$0.17$5.56 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/AN/AN/AN/AN/A
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/AN/AN/AN/AN/A
Cibus, Inc. stock logo
CBUS
Cibus
N/AN/AN/AN/AN/A
Genelux Corporation stock logo
GNLX
Genelux
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
N/A
7.28
7.28
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
N/A
0.70
0.70
Cibus, Inc. stock logo
CBUS
Cibus
N/A
1.62
1.62
Genelux Corporation stock logo
GNLX
Genelux
N/A
2.39
2.39

Institutional Ownership

CompanyInstitutional Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
95.47%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
40.29%
Cibus, Inc. stock logo
CBUS
Cibus
33.81%
Genelux Corporation stock logo
GNLX
Genelux
37.33%

Insider Ownership

CompanyInsider Ownership
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
9.29%
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
29.31%
Cibus, Inc. stock logo
CBUS
Cibus
29.91%
Genelux Corporation stock logo
GNLX
Genelux
7.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Black Diamond Therapeutics, Inc. stock logo
BDTX
Black Diamond Therapeutics
2157.45 million52.12 millionOptionable
BeyondSpring Inc. stock logo
BYSI
BeyondSpring
4441.12 million29.07 millionOptionable
Cibus, Inc. stock logo
CBUS
Cibus
11876.43 million53.57 millionOptionable
Genelux Corporation stock logo
GNLX
Genelux
2645.24 million41.85 millionNot Optionable

Recent News About These Companies

Genelux Corporation (NASDAQ:GNLX) Given Average Rating of "Moderate Buy" by Analysts
September 24 at 2:15 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31043058
Genelux Corporation (NASDAQ:GNLX) Given Average Rating of "Moderate Buy" by Brokerages
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-genelux-corporation-nasdaq-gnlx-given-average-rating-of-moderate-buy-by-brokerages-2026-09-19/
Genelux (NASDAQ:GNLX) Stock Rating Upgraded by Lucid Cap Mkts
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-genelux-nasdaq-gnlx-stock-rating-upgraded-by-lucid-cap-mkts-2026-09-19/
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed ...
September 9, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/genelux-announces-publication-of-a-deep-and-durable-response-in-a-platinum-relapsed-small-cell-lung-cancer-patient-following-systemically-delivered-olvi-vec-primed-immunochemotherapy-1036533892
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3359047/0/en/genelux-announces-publication-of-a-deep-and-durable-response-in-a-platinum-relapsed-small-cell-lung-cancer-patient-following-systemically-delivered-olvi-vec-primed-immunochemothera.html
BlackRock Inc. Takes Position in Genelux Corporation $GNLX
September 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-takes-position-in-genelux-corporation-gnlx-2026-09-07/
Yong Yu Sells 9,683 Shares of Genelux (NASDAQ:GNLX) Stock
September 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-09-03/
Insider Selling: Genelux (NASDAQ:GNLX) Insider Sells 9,683 Shares
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-insider-selling-genelux-nasdaq-gnlx-insider-sells-9683-shares-2026-09-02/
Genelux (NASDAQ:GNLX) CEO Thomas Zindrick Sells 34,463 Shares of Stock
September 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-genelux-nasdaq-gnlx-ceo-thomas-zindrick-sells-34463-shares-of-stock-2026-09-02/
Genelux Reports Second Quarter 2026 Results and Advances Olvi-Vec Clinical Programs in Ovarian and Lung Cancer
August 13, 2026  |  quiverquant.comQ
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344971/0/en/genelux-corporation-reports-second-quarter-financial-results-and-provides-business-updates.html
Genelux (GNLX) Stock Forecast & Price Target
July 11, 2026  |  investing.comhttps://www.investing.com/equities/genelux-consensus-estimates
Genelux (NASDAQ:GNLX) Director John Smither Sells 12,000 Shares of Stock
July 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-07-03/
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
June 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/30/3319590/0/en/genelux-announces-publication-of-translational-analysis-supporting-immune-activation-and-chemotherapy-sensitization-with-olvi-vec-in-ovarian-cancer.html
Genelux Earnings Estimates, EPS & Revenue | NASDAQ:GNLX
June 29, 2026  |  benzinga.comhttps://www.benzinga.com/quote/GNLX/earnings
Insider Selling: Genelux (NASDAQ:GNLX) Director Sells 10,000 Shares of Stock
June 3, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-gnlx-insider-buying-and-selling-2026-06-03/
Genelux Corporation Common Stock (GNLX)
May 25, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/gnlx/institutional-holdings
Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates
May 7, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/07/3290643/0/en/genelux-corporation-reports-first-quarter-financial-results-and-provides-business-updates.html
Genelux Corporation Common Stock (GNLX) Real-Time
April 7, 2026  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/gnlx/real-time
Genelux Establishes $100 Million At-The-Market Equity Program
March 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/genelux-establishes-100-million-at-the-market-equity-program?utm_source=marketbeat.com&utm_medium=referral
Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership Appointment
March 19, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Black Diamond Therapeutics stock logo

Black Diamond Therapeutics NASDAQ:BDTX

$1.90 -0.08 (-4.04%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$1.90 +0.01 (+0.26%)
As of 07:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

BeyondSpring stock logo

BeyondSpring NASDAQ:BYSI

$0.73 -0.01 (-1.85%)
Closing price 09/23/2026 03:59 PM Eastern
Extended Trading
$0.72 0.00 (-0.22%)
As of 07:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.

Cibus stock logo

Cibus NASDAQ:CBUS

$1.54 -0.05 (-3.14%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$1.54 -0.01 (-0.32%)
As of 09/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

Genelux stock logo

Genelux NASDAQ:GNLX

$2.52 -0.09 (-3.45%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$2.52 0.00 (-0.20%)
As of 09/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas